Sanofi Stock

Sanofi EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sanofi (SAN.PA) as of Aug 14, 2026 is 11.37 B EUR. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 10.71 B EUR — a change of 6.22% (higher).

EBITDA

11.37 BEUR

YoY

6.22%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sanofi is 2026 11.37 B EUR. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sanofi was 2025 10.71 B EUR. It decreases by 6.22% higher compared to the previous year.
Access this data via the Eulerpool API

Sanofi Stock analysis

What does Sanofi do? Sanofi SA is a French company that was formed in 1973 from a merger of two French pharmaceutical and biotechnology companies. It is one of the largest players in the healthcare industry worldwide and employs over 100,000 employees. The objective of Sanofi is to improve people's lives through innovative medicines and therapies. In this regard, the company pursues a comprehensive business model that focuses on both research and development, as well as the production and distribution of medications and vaccines. The company has different divisions and product lines, which are divided into three business areas: Innovative Medicine, Consumer Healthcare, and Generic Pharmaceuticals. Innovative Medicine utilizes state-of-the-art technologies and scientific knowledge to treat the most challenging diseases. In the area of Consumer Healthcare, the company offers a wide range of over-the-counter products such as vitamins, dietary supplements, cough and cold remedies, as well as oral and dental health products. In the Generic Pharmaceuticals field, the company produces more cost-effective alternatives to expensive brand-name products, providing a variety of generic medications. Sanofi is a leading manufacturer of medications that are of great significance in various areas such as diabetes, oncology, cardiovascular diseases, and neurology. In recent years, the company has also established a strong presence in the field of vaccines. Here, Sanofi develops and produces innovative vaccines against COVID-19, influenza, and other infectious diseases. Sanofi is present in more than 170 countries and collaborates closely with physicians, research institutions, and health authorities to improve healthcare worldwide. The company conducts research and development in various disciplines and invests a significant amount each year in the development of innovative medicines and therapies. Overall, Sanofi SA is an emerging company in the pharmaceutical and healthcare sector. The portfolio of products and therapies offered by Sanofi is extensive and covers many areas of healthcare. Sanofi relies on continuous innovation and continuously works to improve healthcare and enhance the lives of people worldwide. Sanofi is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sanofi stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sanofi is 11.37 B EUR in 2026.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sanofi changed from 10.71 B EUR to 11.37 B EUR, representing a 6.22% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Sanofi since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Sanofi historically and in real time.

Access this data via the Eulerpool API

Income Statement — Sanofi

All Key Metrics — Sanofi